User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Primary tabs

Roy, A Cunningham, D Hawkins, R Sörbye, H Adenis, A D'Hondt, Lionel [UCL] Misset, J-L

Both docetaxel-based doublet regimens show comparable efficacy; however, the DF regimen was associated with a better toxicity profile and is an alternative treatment option for patients in whom platinum-based regimens are unsuitable.

Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2012
Language Anglais
Journal information "The British journal of cancer" - Vol. 107, no.3, p. 435-41 (2012)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) [S.l.])
issn 0007-0920
e-issn 1532-1827
Publication status Publié
Affiliations UCL - SSS/IREC - Institut de recherche expérimentale et clinique
UCL - (MGD) Service d'oncologie médicale
MESH Subject Adult ; Male ; Middle Aged ; Stomach Neoplasms ; Taxoids ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Camptothecin ; Disease Progression ; Esophageal Neoplasms ; Female ; Fluorouracil ; Humans
Links
  1. Ajani Jaffer A., Fodor Miguel B., Tjulandin Sergei A., Moiseyenko Vladimir M., Chao Yee, Filho Sebastiao Cabral, Majlis Alejandro, Assadourian Sylvie, Van Cutsem Eric, Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma, 10.1200/jco.2005.17.376
  2. Assersohn L., Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, 10.1093/annonc/mdh007
  3. Bang Yung-Jue, Van Cutsem Eric, Feyereislova Andrea, Chung Hyun C, Shen Lin, Sawaki Akira, Lordick Florian, Ohtsu Atsushi, Omuro Yasushi, Satoh Taroh, Aprile Giuseppe, Kulikov Evgeny, Hill Julie, Lehle Michaela, Rüschoff Josef, Kang Yoon-Koo, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, 10.1016/s0140-6736(10)61121-x
  4. Boku Narikazu, Yamamoto Seiichiro, Fukuda Haruhiko, Shirao Kuniaki, Doi Toshihiko, Sawaki Akira, Koizumi Wasaburo, Saito Hiroshi, Yamaguchi Kensei, Takiuchi Hiroya, Nasu Junichiro, Ohtsu Atsushi, Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study, 10.1016/s1470-2045(09)70259-1
  5. Constenla Manuel, Garcia-Arroyo Ramon, Lorenzo Isabel, Carrete Nancy, Campos Begoña, Palacios Patricia, Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study, 10.1007/s101200200025
  6. Cunningham David, Starling Naureen, Rao Sheela, Iveson Timothy, Nicolson Marianne, Coxon Fareeda, Middleton Gary, Daniel Francis, Oates Jacqueline, Norman Andrew Richard, Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer, 10.1056/nejmoa073149
  7. Dank M, ASCO Meeting Abstracts, 23, 4003 (2005)
  8. Giordano K. F., Jatoi A., Stella P. J., Foster N., Tschetter L. K., Alberts S. R., Dakhil S. R., Mailliard J. A., Flynn P. J., Nikcevich D. A., Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group, 10.1093/annonc/mdl005
  9. Hawkes Eliza, Okines Alicia F.C., Papamichael Demetris, Rao Sheela, Ashley Sue, Charalambous Haris, Koukouma Alona, Chau Ian, Cunningham David, Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer, 10.1016/j.ejca.2010.12.021
  10. Jatoi Aminah, Tirona Marisa Tria, Cha Steven S., Alberts Steven R., Rowland Kendrith M., Morton Roscoe F., Nair Suresh, Kardinal Carl G., Stella Philip J., Mailliard James A., Sargen Daniel, Goldberg Richard M., A Phase II Trial of Docetaxel and CPT-11 in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia, 10.1385/ijgc:32:2-3:115
  11. Jemal Ahmedin, Bray Freddie, Center Melissa M., Ferlay Jacques, Ward Elizabeth, Forman David, Global cancer statistics, 10.3322/caac.20107
  12. Kang Jung Hun, Lee Soon Il, Lim Do Hyoung, Park Keon-Woo, Oh Sung Yong, Kwon Hyuk-Chan, Hwang In Gyu, Lee Sang-Cheol, Nam Eunmi, Shin Dong Bok, Lee Jeeyun, Park Joon Oh, Park Young Suk, Lim Ho Yeong, Kang Won Ki, Park Se Hoon, Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone, 10.1200/jco.2011.39.4585
  13. Kim Seok Hyun, Lee Gyeong-Won, Go Se il, Cho Su Hee, Kim Hyun Jin, Kim Hun Gu, Kang Jung Hun, A Phase II Study of Irinotecan, Continuous 5-Fluorouracil, and Leucovorin (FOLFIRI) Combination Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer Previously Treated With a Fluoropyrimidine-Based Regimen : , 10.1097/coc.0b013e3181bead7b
  14. Köhne C-H, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Betta D Di, Jacques C, Wilke H J, Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial, 10.1038/sj.bjc.6601226
  15. Miller A. B., Hoogstraten B., Staquet M., Winkler A., Reporting results of cancer treatment, 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
  16. Park S R, Chun J H, Yu M S, Lee J H, Ryu K W, Choi I J, Kim C G, Lee J S, Kim Y W, Bae J-M, Kim H K, Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma, 10.1038/sj.bjc.6603133
  17. Pozzo C., Barone C., Szanto J., Padi E., Peschel C., Bükki J., Gorbunova V., Valvere V., Zaluski J., Biakhov M., Zuber E., Jacques C., Bugat R., Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study, 10.1093/annonc/mdh473
  18. Shah MA, ASCO Meeting Abstracts, 28, 4014 (2010)
  19. Sym Sun Jin, Chang Heung Moon, Kang Hye Jin, Lee Sung Sook, Ryu Min-Hee, Lee Jae-Lyun, Kim Tae-Won, Yook Jeong Hwan, Oh Sung Tae, Kim Byung Sik, Kang Yoon-Koo, A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer, 10.1007/s00280-008-0701-2
  20. Tebbutt N C, Cummins M M, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J, Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial, 10.1038/sj.bjc.6605522
  21. Thuss-Patience Peter C., Kretzschmar Albrecht, Bichev Dmitry, Deist Tillman, Hinke Axel, Breithaupt Kirstin, Dogan Yasemin, Gebauer Bernhard, Schumacher Guido, Reichardt Peter, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), 10.1016/j.ejca.2011.06.002
  22. Thuss-Patience Peter C., Kretzschmar Albrecht, Repp Michael, Kingreen Dorothea, Hennesser Dirk, Micheel Simone, Pink Daniel, Scholz Christian, Dörken Bernd, Reichardt Peter, Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study, 10.1200/jco.2005.02.163
  23. Van Cutsem E, ASCO Meeting Abstracts, 29, 4018 (2011a)
  24. Van Cutsem E., Dicato M., Geva R., Arber N., Bang Y., Benson A., Cervantes A., Diaz-Rubio E., Ducreux M., Glynne-Jones R., Grothey A., Haller D., Haustermans K., Kerr D., Nordlinger B., Marshall J., Minsky B. D., Kang Y. K., Labianca R., Lordick F., Ohtsu A., Pavlidis N., Roth A., Rougier P., Schmoll H. J., Sobrero A., Tabernero J., Van de Velde C., Zalcberg J., The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010, 10.1093/annonc/mdr284
  25. Van Cutsem Eric, Moiseyenko Vladimir M., Tjulandin Sergei, Majlis Alejandro, Constenla Manuel, Boni Corrado, Rodrigues Adriano, Fodor Miguel, Chao Yee, Voznyi Edouard, Risse Marie-Laure, Ajani Jaffer A., Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group, 10.1200/jco.2006.06.8429
  26. Wagner AD, Cochrane Database Syst Rev, 3, CD004064 (2010)
  27. Wesolowski Robert, Lee Chan, Kim Richard, Is there a role for second-line chemotherapy in advanced gastric cancer?, 10.1016/s1470-2045(09)70136-6
  28. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y, Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer, 10.1038/sj.bjc.6603196
  29. Yoshida K., Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer, 10.1158/1078-0432.ccr-05-2425
Bibliographic reference Roy, A ; Cunningham, D ; Hawkins, R ; Sörbye, H ; Adenis, A ; et. al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.. In: The British journal of cancer, Vol. 107, no.3, p. 435-41 (2012)
Permanent URL http://hdl.handle.net/2078.1/124737